Gland Pharma

{
  "main_header": {
    "sid": 1003443,
    "name": "Gland Pharma",
    "stock_name": "Gland Pharma",
    "full_name": "Gland Pharma Ltd",
    "name_url": "stocks-analysis/gland-pharma",
    "exchange": 0,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "1,802.75",
    "chg": 114.05,
    "chgp": "6.75%",
    "dir": 1,
    "prev_price": "1,688.70",
    "mcapval": "29,178.00 Cr",
    "mcap": "Small Cap",
    "scripcode": 543245,
    "symbol": "GLAND",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "",
    "isin": "INE068V01023",
    "curr_date": "Jan 29",
    "curr_time": "",
    "bse_nse_vol": "32.77 lacs",
    "exc_status": "Active",
    "traded_date": "Jan 29, 2026",
    "traded_date_str": "2026 01 29",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/gland-pharma-1003443-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Are Gland Pharma Ltd latest results good or bad?",
        "link": "https://www.marketsmojo.com/news/result-analysis/are-gland-pharma-ltd-latest-results-good-or-bad-3810125",
        "imagepath": "",
        "date": "2026-01-29 19:25:24",
        "description": "Gland Pharma Ltd's latest financial results for Q3 FY26 reveal a complex picture of operational performance. The company reported a net profit of ₹279.06 crores, reflecting a year-on-year growth of 36.30%, while revenue reached ₹1,695.36 crores, marking a 22.49% increase compared to the same quarter last year. This revenue figure represents a sequential growth of 14.02% from the previous quarter, indicating strong demand, particularly in its injectable portfolio and key export markets like the United States.\n\nHowever, the operating margin has come under pressure, decreasing to 19.07%, down 201 basis points year-on-year. This decline is attributed to rising employee costs and increased manufacturing expenses as Gland Pharma scales its production capacity. Despite the growth in revenue and net profit margins, which improved to 16.46% from 14.79% in the prior year, the reliance on exceptional other income, whi..."
      },
      {
        "title": "Gland Pharma Ltd Hits Intraday High with 7.6% Surge on 29 Jan 2026",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/gland-pharma-ltd-hits-intraday-high-with-76-surge-on-29-jan-2026-3808981",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/1/GlandPharmaLtd_priceRelatedfactors_3808981.png",
        "date": "2026-01-29 09:32:58",
        "description": "Gland Pharma Ltd recorded a robust intraday performance on 29 Jan 2026, surging to an intraday high of Rs 1849, marking a 9.49% rise from its previous close. The stock outperformed its sector and broader market indices, reflecting significant trading momentum and volatility throughout the session."
      },
      {
        "title": "Gland Pharma Ltd Opens Strong with Significant Gap Up on 29 Jan 2026",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/gland-pharma-ltd-opens-strong-with-significant-gap-up-on-29-jan-2026-3808967",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/1/GlandPharmaLtd_gapup_3808967.png",
        "date": "2026-01-29 09:31:33",
        "description": "Gland Pharma Ltd commenced trading on 29 Jan 2026 with a significant gap up, opening 7.72% higher than its previous close. This strong start underscores a positive market sentiment towards the pharmaceutical company amid a backdrop of notable outperformance relative to its sector and benchmark indices."
      },
      {
        "title": "Gland Pharma Ltd Reports Strongest Quarterly Performance Amid Positive Financial Trend",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/gland-pharma-ltd-reports-strongest-quarterly-performance-amid-positive-financial-trend-3808624",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/1/GlandPharmaLtd_fintrenddot_3808624.png",
        "date": "2026-01-29 08:00:25",
        "description": "Gland Pharma Ltd has delivered its highest quarterly financial results to date in the December 2025 quarter, signalling a marked improvement in its financial trajectory. The company’s net sales, profitability, and earnings per share have all reached record levels, reflecting a positive shift from a previously flat financial trend and prompting a downgrade in its Mojo Grade from Hold to Sell."
      },
      {
        "title": "Gland Pharma Q3 FY26: Strong Quarter Masked by Valuation Concerns",
        "link": "https://www.marketsmojo.com/news/result-analysis/gland-pharma-q3-fy26-strong-quarter-masked-by-valuation-concerns-3808299",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/1/GlandPharma_quaterlyResult_3808299.png",
        "date": "2026-01-28 19:03:06",
        "description": "Gland Pharma Ltd., the Hyderabad-based injectable pharmaceuticals specialist, delivered a robust performance in Q3 FY26 with net profit surging 36.30% year-on-year to ₹279.06 crores, marking its strongest quarterly showing in recent history. However, the stock's muted response—trading at ₹1,688.70 with a modest 0.80% gain—reflects investor caution over stretched valuations, with shares trading at 35 times trailing earnings despite persistent profitability concerns and declining returns on equity."
      },
      {
        "title": "Gland Pharma Ltd is Rated Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/gland-pharma-ltd-is-rated-sell-3807287",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/1/GlandPharmaLtd_mojoScore_3807287.png",
        "date": "2026-01-28 10:10:35",
        "description": "Gland Pharma Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 05 Jan 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 28 January 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook."
      },
      {
        "title": "Gland Pharma Ltd Technical Momentum Shifts Amid Bearish Signals",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/gland-pharma-ltd-technical-momentum-shifts-amid-bearish-signals-3793778",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/1/GlandPharmaLtd_technicaldot_3793778.png",
        "date": "2026-01-19 08:03:37",
        "description": "Gland Pharma Ltd has experienced a notable shift in its technical momentum, with key indicators signalling a transition from mildly bearish to bearish trends. The stock’s recent price action, combined with deteriorating moving averages and mixed signals from momentum oscillators, suggests increasing downside pressure amid a challenging market environment."
      },
      {
        "title": "Gland Pharma Declines 1.88%: Downgrade and Bearish Technicals Weigh on Shares",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/gland-pharma-declines-188-downgrade-and-bearish-technicals-weigh-on-shares-3788208",
        "imagepath": "",
        "date": "2026-01-10 12:01:42",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <div class=\"highlight-box\">\n                    <h3>Key Events This Week</h3>\n                    <p><strong>5 Jan:</strong> Downgrade to Sell rating by MarketsMOJO amid weak financials</p>\n                    <p><strong>6 Jan:</strong> Mildly bearish technical shift confirmed with mixed momentum signals</p>\n                    <p><strong>7 Jan:</strong> Formation of Death Cross signalling potential bearish trend</p>\n                    <p><strong>8 Jan:</strong> Bearish momentum intensifies despite modest intraday gains</p>\n                </div>\n\n                <div class=\"stats-row\">\n                    <div class=\"stat-item\"><div class=\"stat-label\">Week Open</div><div class=\"stat-value\">Rs.1,712.90</div></div>\n                    <div class=\"stat-item\"><div class=\"stat-label\">Week C..."
      },
      {
        "title": "Gland Pharma Ltd Faces Bearish Momentum Amid Technical Downturn",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/gland-pharma-ltd-faces-bearish-momentum-amid-technical-downturn-3785151",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/1/GlandPharmaLtd_technicaldot_3785151.png",
        "date": "2026-01-08 08:22:44",
        "description": "Gland Pharma Ltd has experienced a notable shift in its technical momentum, with key indicators signalling a transition from mildly bearish to bearish trends. Despite a modest intraday price increase, the stock’s broader technical landscape suggests caution for investors amid weakening momentum and mixed signals from momentum oscillators and moving averages."
      }
    ],
    "total": 330,
    "sid": "1003443",
    "stock_news_url": "https://www.marketsmojo.com/news/gland-pharma-1003443"
  },
  "announcements": [
    {
      "caption": "Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018",
      "datetime": "13-Jan-2026",
      "details": "Certificate under Reg 74(5) of SEBI (DP) Regulations 2018",
      "source": "BSE"
    },
    {
      "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation",
      "datetime": "09-Jan-2026",
      "details": "Q3FY26 Earnings Call Intimation",
      "source": "BSE"
    },
    {
      "caption": "Board Meeting Intimation for Declaration Of Unaudited Financial Results For The Quarter And Nine Months Ended December 31 2025",
      "datetime": "09-Jan-2026",
      "details": "Gland Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 28/01/2026 inter alia to consider and approve Unaudited Financial Results for the quarter and nine months ended December 31 2025",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Gland Pharma Ltd has declared <strong>1800%</strong> dividend, ex-date: 14 Aug 25",
          "dt": "2025-08-14",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Are Gland Pharma Ltd latest results good or bad?

2026-01-29 19:25:24

Gland Pharma Ltd's latest financial results for Q3 FY26 reveal a complex picture of operational performance. The company reported a net profit of ₹279.06 crores, reflecting a year-on-year growth of 36.30%, while revenue reached ₹1,695.36 crores, marking a 22.49% increase compared to the same quarter last year. This revenue figure represents a sequential growth of 14.02% from the previous quarter, indicating strong demand, particularly in its injectable portfolio and key export markets like the United States. However, the operating margin has come under pressure, decreasing to 19.07%, down 201 basis points year-on-year. This decline is attributed to rising employee costs and increased manufacturing expenses as Gland Pharma scales its production capacity. Despite the growth in revenue and net profit margins, which improved to 16.46% from 14.79% in the prior year, the reliance on exceptional other income, whi...

Read full news article

Gland Pharma Ltd Hits Intraday High with 7.6% Surge on 29 Jan 2026

2026-01-29 09:32:58

Gland Pharma Ltd recorded a robust intraday performance on 29 Jan 2026, surging to an intraday high of Rs 1849, marking a 9.49% rise from its previous close. The stock outperformed its sector and broader market indices, reflecting significant trading momentum and volatility throughout the session.

Read full news article

Gland Pharma Ltd Opens Strong with Significant Gap Up on 29 Jan 2026

2026-01-29 09:31:33

Gland Pharma Ltd commenced trading on 29 Jan 2026 with a significant gap up, opening 7.72% higher than its previous close. This strong start underscores a positive market sentiment towards the pharmaceutical company amid a backdrop of notable outperformance relative to its sector and benchmark indices.

Read full news article

Gland Pharma Ltd Reports Strongest Quarterly Performance Amid Positive Financial Trend

2026-01-29 08:00:25

Gland Pharma Ltd has delivered its highest quarterly financial results to date in the December 2025 quarter, signalling a marked improvement in its financial trajectory. The company’s net sales, profitability, and earnings per share have all reached record levels, reflecting a positive shift from a previously flat financial trend and prompting a downgrade in its Mojo Grade from Hold to Sell.

Read full news article

Gland Pharma Q3 FY26: Strong Quarter Masked by Valuation Concerns

2026-01-28 19:03:06

Gland Pharma Ltd., the Hyderabad-based injectable pharmaceuticals specialist, delivered a robust performance in Q3 FY26 with net profit surging 36.30% year-on-year to ₹279.06 crores, marking its strongest quarterly showing in recent history. However, the stock's muted response—trading at ₹1,688.70 with a modest 0.80% gain—reflects investor caution over stretched valuations, with shares trading at 35 times trailing earnings despite persistent profitability concerns and declining returns on equity.

Read full news article

Gland Pharma Ltd is Rated Sell

2026-01-28 10:10:35

Gland Pharma Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 05 Jan 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 28 January 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Read full news article

Gland Pharma Ltd Technical Momentum Shifts Amid Bearish Signals

2026-01-19 08:03:37

Gland Pharma Ltd has experienced a notable shift in its technical momentum, with key indicators signalling a transition from mildly bearish to bearish trends. The stock’s recent price action, combined with deteriorating moving averages and mixed signals from momentum oscillators, suggests increasing downside pressure amid a challenging market environment.

Read full news article

Gland Pharma Declines 1.88%: Downgrade and Bearish Technicals Weigh on Shares

2026-01-10 12:01:42

Key Events This Week

5 Jan: Downgrade to Sell rating by MarketsMOJO amid weak financials

6 Jan: Mildly bearish technical shift confirmed with mixed momentum signals

7 Jan: Formation of Death Cross signalling potential bearish trend

8 Jan: Bearish momentum intensifies despite modest intraday gains

Week Open

Rs.1,712.90

Week C...

Read full news article

Gland Pharma Ltd Faces Bearish Momentum Amid Technical Downturn

2026-01-08 08:22:44

Gland Pharma Ltd has experienced a notable shift in its technical momentum, with key indicators signalling a transition from mildly bearish to bearish trends. Despite a modest intraday price increase, the stock’s broader technical landscape suggests caution for investors amid weakening momentum and mixed signals from momentum oscillators and moving averages.

Read full news article

View All News